Aerie Pharmaceuticals, Inc. (AERI) stock prices updated...
 

Aerie Pharmaceuticals, Inc. stock price

Aerie Pharmaceuticals, Inc. latest news:


  • 12/19/2017 04:30:21

    BRIEF-Aerie Pharma Enters Controlled Equity Offering Sales Agreement With Cantor Fitzgerald

    Aerie Pharmaceuticals Inc(AERI): * AERIE PHARMA SAYS ON DEC 19, CO ENTERED INTO CONTROLLED EQUITY OFFERINGSALES AGREEMENT WITH CANTOR FITZGERALD - SEC FILING. * AERIE PHARMACEUTICALS(AERI) - PURSUANT TO AGREEMENT, CO MAY OFFER AND SELL SHARES, PAR VALUE $0.001 PER SHARE, HAVING OFFERING PRICE OF UP TO $75 MILLION Source text: Further company coverage:

  • 12/18/2017 15:20:52

    UPDATE 2-Aerie's glaucoma treatment gets early FDA approval

    Dec 18 (Reuters) - Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.

  • 12/18/2017 14:48:07

    Aerie's glaucoma treatment gets early FDA approval

    Aerie Pharmaceuticals Inc(AERI) said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date. Glaucoma affects about 2.7 million people in the United States and is the second leading cause of blindness in the world.

  • 12/18/2017 14:47:53

    UPDATE 1-Aerie's glaucoma treatment gets early FDA approval

    Dec 18 (Reuters) - Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.

  • 12/18/2017 14:47:43

    Aerie Pharma eye drug Rhopressa approved by FDA

    Aerie Pharmaceuticals Inc. announced Monday afternoon that the Food and Drug Administration has approved a medication developed to relieve pressure in patients suffering from glaucoma or ocular hypertension. Chief Executive Vicente Anido said in the announcement that the approval of Rhopressa "represents the single greatest achievement in Aerie's history to date." Anido said that the company plans to hire a sales force for the drug early in the first quarter of 2018 and will seek to launch sales in by the middle of the second quarter. Aerie shares were halted ahead of the announcement, then declined about 3% in late trading.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    AeroVironment, Inc.AVAV | AEterna Zentaris Inc.AEZS | Aethlon Medical, Inc.AEMD | Affimed N.V.AFMD | Affymetrix, Inc.AFFX | Agenus Inc.AGEN | Agile Therapeutics, Inc.AGRX | Agilysys, Inc.AGYS | Agios Pharmaceuticals, Inc.AGIO | AgroFresh Solutions, Inc.AGFS |